CIK 0000727510 · Non-accelerated filer<br>Smaller reporting company
Viskase Holdings, Inc.
Sign in to watch- Ticker
- VISK
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 222372868
- Phone
- (630) 874-0700
- Business address
- 333 EAST BUTTERFIELD ROAD, SUITE 400, LOMBARD, IL, 60148
- Former names
- ENZON PHARMACEUTICALS, INC., ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICAL INC, ENZON INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2012-01-17 | Rackear Andrew D. VP and General Counsel | Grant or award | +10,000 | 58,334 | ||
| 2012-01-17 | Rackear Andrew D. VP and General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2012-01-17 | Greenberger Lee M VP, Research | Grant or award | +3,500 | 36,146 | ||
| 2012-01-17 | Greenberger Lee M VP, Research | Grant or award · Employee Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2012-01-17 | Stancic Ana Executive VP, COO, PEO, CFO | Returned to the company | −45,000 | 15,000 | ||
| 2012-01-17 | Stancic Ana Executive VP, COO, PEO, CFO | Grant or award | +45,000 | 70,000 | ||
| 2012-01-03 | Deuel Thomas Director | Grant or award · Stock Option (Right to Buy) | +10,994 | 10,994 | ||
| 2012-01-03 | Mulligan Richard Director | Grant or award · Stock Option (Right to Buy) | +19,240 | 19,240 | ||
| 2012-01-03 | SALISBURY ROBERT C Director | Grant or award · Stock Option (Right to Buy) | +10,994 | 10,994 | ||
| 2012-01-03 | Young Richard A Director | Grant or award · Stock Option (Right to Buy) | +10,994 | 10,994 | ||
| 2012-01-03 | LEBUHN ROBERT Director | Grant or award · Stock Option (Right to Buy) | +10,994 | 10,994 | ||
| 2012-01-03 | DENNER ALEXANDER J Director | Grant or award · Stock Option (Right to Buy) | +21,988 | 21,988 | ||
| 2011-12-19 | Daly Timothy VP, Controller and PAO | Grant or award · Employee Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2011-11-17 | Stancic Ana Executive VP, COO, PEO CFO | Grant or award · Employee Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2011-11-17 | Stancic Ana Executive VP, COO, PEO, CFO | Grant or award | +45,000 | 70,000 | ||
| 2011-11-17 | Stancic Ana Executive VP, COO, PEO, CFO | Grant or award · Employee Stock Option (Right to Buy) | +125,000 | 155,000 | ||
| 2011-11-10 | Rackear Andrew D. VP and General Counsel | Sale | −3,766 | $6.68 | $25K | 48,334 |
| 2011-11-08 | Buchbinder Aby VP, Clinical Development | Sale | −2,700 | $7.06 | $19K | 54,015 |
| 2011-09-15 | Greenberger Lee M VP, Research | Shares withheld for taxes | −591 | $8.33 | $5K | 32,646 |
| 2011-09-15 | del Campo Ralph COO and Princ. Exec. Officer | Shares withheld for taxes | −886 | $8.33 | $7K | 204,633.14 |
Page 7 of 12 · 223 trades